Tag results:

Industry & Policy News

IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate

[International AIDS Vaccine Initiative, Inc.] IAVI announced that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the US. The IAVI-sponsored trial was funded by the Biomedical Advanced Research and Development Authority.

A Blow to Cancer Research in the UK As National Cancer Institute Closes Down

[Clinical Trial Arena] The UK’s National Cancer Research Institute (NCRI) is winding down operations and working on identifying and securing assets. The NCRI reported that it was becoming increasingly “unsustainable” to continue to fund the charitable organisation.

Cancer Researcher Dr. Ly Vu Receives Funding from Program Challenging Gender Disparities

[The University of British Columbia] This new granting program, developed by the V Foundation for Cancer Research, sees $8 million in funding invested in cancer research being led by women scientists. Dr. Vu is an associate assistant professor in the faculty of medicine and an assistant professor in the faculty of pharmaceutical sciences at UBC. She was also cross-appointed at the BC Cancer Research Institution as a scientist in the Terry Fox Laboratory.

Rezolute to Initiate a Pivotal Phase III Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

[Rezolute, Inc.] Rezolute, Inc. plans to initiate sunRIZE, a pivotal Phase II clinical study of RZ358, in Europe and other geographies outside the US in Q4 2023.

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of...

[Beyond Air, Inc.] Beyond Air, Inc. announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. to license the commercial rights for multiple nNOS inhibitor candidates, currently being developed for the treatment of autism spectrum disorder and other neurological conditions.

European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies

[ONK Therapeutics, Ltd.] ONK Therapeutics, Ltd. announced that the European Patent Office granted its licensed patent covering CISH knockout in natural killer (NK) cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from iPSCs.

Popular